Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00032799 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease
A Phase 3 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 3
- Development phase
- 905
- Enrollment target
NCT00032799 is a Phase 3 study that has completed, run by Biogen. The registered enrollment target is 905 participants.
The verdict
NCT00032799, a Phase 3 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 905 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of natalizumab in individuals diagnosed with moderately to severely active Crohn's disease. It is thought that natalizumab may stop the movement of certain cells, known as white blood cells, into bowel tissue. These cells are thought to cause damage in the bowel leading to the symptoms of Crohn's disease.
Interventions
- DRUG natalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 905 participants |
| Start Date | 2001-12 |
| Est. Completion | 2003-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00032799
The ClinicalTrials.gov registry entry for NCT00032799 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 905 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which natalizumab is the first listed.
NCT00032799 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00032799 about?
NCT00032799 is a clinical study titled "Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease". The purpose of this study is to determine the safety and efficacy of natalizumab in individuals diagnosed with moderately to severely active Crohn's disease. It is thought that natalizumab may stop the movement of certain cells, known as white blood cells, into bowel tissue. These cells are thought ...
What is the current status of trial NCT00032799?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 905 participants. The study started on 2001-12. Estimated completion is 2003-09.
What interventions are being tested in trial NCT00032799?
The interventions under investigation include: natalizumab (DRUG).
Who is sponsoring clinical trial NCT00032799?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.